课题基金 / 基金详情

NATURAL HISTORY OF ARTHRITIS AND RHEUMATISM ON THE GILA RIVER INDIAN COMMUNITY

NATURAL HISTORY OF ARTHRITIS AND RHEUMATISM ON THE GILA RIVER INDIAN COMMUNITY
吉拉河印第安社区关节炎和风湿病的自然史
批准号:
3918287
负责人:
P H BENNETT
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

P H BENNETT的其他基金

相似基金

相关文献

中文摘要
翻译
骨关节病、类风湿性关节炎的发生发展 关节炎和强直性脊柱炎正在通过 进行的临床、放射和血清学检查 预期每隔两年在吉拉的成年人中进行一次 亚利桑那州的河流印第安人社区(皮马印第安人) 与糖尿病的流行病学研究在同一社区。 这项调查的目的是确定决定因素。 这些疾病在人群中的分布情况,并确定哪些因素 改变疾病发展的自然历史。寄主 年龄、性别和包括人类白细胞抗原在内的各种基因标记物 和通用汽车,连同各种潜在的环境决定因素, 如肥胖和接触感染物的证据,将 进行前瞻性研究,以确定它们与 这些疾病的发展。纵向数据现在已经 20多年来收集的数据,代表了 关节炎的流行病学研究。
英文摘要
The development and progression of osteoarthrosis, rheumatoid arthritis and ankylosing spondylitis are being determined by means of clinical, radiographic and serological examinations carried out prospectively at two-yearly intervals among adults of the Gila River Indian Community (Pima Indians) in Arizona, in conjunction with epidemiological studies of diabetes in the same community. The purpose of this investigation is to ascertain the determinants of these diseases in the population, and to identify factors which alter the natural history of progression of the disease. Host factors such as age, sex, and various gene markers including HLA and Gm, together with various potential environmental determinants, such as obesity and evidence of exposure to infectious agents, will be studied prospectively to determine their relationship to the development of these diseases. Longitudinal data have now been collected over 20 years and represent a unique data set for epidemiological studies of arthritis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
GILA RIVER INDIAN COMMUNITY AUTOPSY AND MORTALITY STUDY
GILA RIVER INDIAN COMMUNITY AUTOPSY AND MORTALITY STUDY
DIABETES, ARTHRITIS, AND OTHER METABOLIC DISEASES IN THE PACIFIC REGION
NATURAL HISTORY OF ARTHRITIS AND RHEUMATISM ON THE GILA RIVER INDIAN COMMUNITY
国内基金
海外基金
Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data